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that the quantitative assessment of the
effectiveness of public health inter-
vention measures for SARS is a diffi-
cult task for modelers. To make mod-
els useful for assessing the effects of
specific intervention measures and for
predicting the future dynamics during
an ongoing epidemic, we need
improved knowledge on the transmis-
sion mechanisms, pathogenesis, and
the epidemiologic determinants of the
spread of the virus. Any retrospective
analysis of the 2003 SARS epidemic
that improves our knowledge of
SARS epidemiology is welcome. 
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To the Editor: A novel coron-
avirus caused more than 8,000 proba-
ble cases of severe acute respiratory
syndrome (SARS) worldwide (1,2)
during the 2003 outbreak. Before the
etiologic agent was identified, the
diagnosis of SARS was made accord-
ing to a set of clinical-epidemiologic
criteria as suggested by the Centers
for Disease Control and Prevention
(CDC) (1–3). These criteria remained
important in the initial diagnosis and
prompt isolation of patients because
the overall sensitivity of initial reverse
transcriptase-polymerase chain reac-
tion (RT–PCR) testing for SARS-
associated coronavirus (SARS CoV)
RNA on upper respiratory specimens
ranged from approximately 60% to
70% (though sensitivity improved
with a second test) (4,5). In a SARS
screening clinic at the Prince of
Wales emergency department, the
positive predictive value (PPV) of
these criteria was estimated to be
54% (95% CI 39% to 69%) (6). The
relative importance of the clinical
versus epidemiologic criteria had not
been evaluated. By using paired sero-
logic testing to determine SARS-CoV
infection (3), we evaluated the rela-
tive importance of the clinical-epi-
demiologic diagnostic criteria during
an outbreak. 
Patients with a diagnosis of SARS,
and who were admitted to one of five
regional hospitals in Hong Kong for
isolation and treatment from March 4
to June 6, 2003, were included in this
retrospective analysis. Probable
SARS case-patients were those who
met the CDC clinical criteria for
severe respiratory illness of unknown
etiology (3), and met the epidemio-
logic criterion for exposure in either a
close or a possible contact. Close con-
tact was defined as caring for, living
with, or having direct contact with
body fluids of a probable SARS
patient (e.g., working in the same
medical ward or staying in the same
household) within 10 days of initial
symptoms. Because Hong Kong was
the documented SARS transmission
site from February 1 to July 11, 2003,
a modified epidemiologic criterion of
possible contact was adopted.
Possible contact was defined as stay-
ing or working in the same hospital
compound, or residing in the same
building where case clusters of SARS
had been reported, within 10 days of
symptoms onset. 
Laboratory testing of paired
immunoglobulin (Ig) G antibody to
SARS-CoV was used to determine
infection (7). Positive serologic evi-
dence of infection was defined as a
four-fold rise in antibody titer or
detection of antibody in convalescent-
phase serum. Seronegativity was
defined as absence of antibody in con-
valescent-phase serum obtained >21
days after symptom onset (3).
Seronegativity in this defined time
frame (>21 days – serum collected
before July 11, 2003, and beyond 28
days) excluded the diagnosis of SARS
(3). Samples from patients showing
nonspecific fluorescent signals were
considered negative for SARS-CoV
infection. RT-PCR was performed on
clinical specimens (respiratory, fecal)
from all patients (1,3–5).
Demographic and laboratory
parameters and history of close con-
tact were compared between the
seropositive and seronegative groups.
Student t test was used to analyze con-
tinuous variables. A p value of <0.05
was considered statistically signifi-
cant. Odds ratio (OR) and 95% confi-
dence interval (CI) were calculated
for categorical variables. 
During the study period, 475
patients were hospitalized with proba-
ble SARS. One hundred patients were
excluded because their serologic
results were either missing (n = 37) or
they died before day 21 of illness (no
convalescent-phase serum, n = 63).
Three hundred seventy-five patients
were included in the analyses; 353
(94.1%) patients were serology-posi-
tive for SARS-CoV. Two hundred
sixty-three of the 353 patients
(74.5%) had a 4-fold increase in anti-
body titers, and 90 of the 353 patients
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(25.5%) had detectable antibody in
either acute- or convalescent-phase
serum samples (titer 80–5,120).
Twenty-two patients (5.9%) had anti-
body titer <40 in their convalescent-
phase serum samples (median = 31
days; range = 21–61 days). No clini-
cal specimens were positive for
SARS-CoV by RT-PCR. Thus, the
PPV of the clinical-epidemiologic cri-
teria for SARS in our cohort was 0.94
(95% CI 0.91–0.96).
The contact history and demo-
graphic and laboratory parameters for
both seropositive and seronegative
groups are depicted in the Table. The
proportion of patients with a history of
close contact was significantly higher
in the seropositive group than in the
seronegative group (91.2% vs 31.8%,
OR 22.3; 95% CI 8.4–58.7). Only
8.8% of the patients with serological-
ly confirmed results had no close con-
tact history; 68.2% of the seronegative
patients were in this category. The
PPV of close contact was 0.98 (95%
CI 0.96–0.99), and the PPV of possi-
ble contact was 0.67 (95% CI
0.54–0.81). Seropositive patients had
a significantly lower lymphocyte
count on admission compared to the
seronegative patients (1.0 ± 0.4 vs 1.2
± 0.8 x 109/L) (p = 0.027). The PPVs
for possible contact plus lymphopenia
<0.8 x 109/L and <1.0 x 109/L were
0.76 (95% CI 0.56–0.97) and 0.72
(95% CI 0.56–0.89), respectively.
Seronegative patients were older (51.2
± 24.3 vs. 40.9 ± 17.2 years), were
less likely to be healthcare workers
(90.9% vs. 45.3%), had their venue of
contact in the community (63.6% vs.
17.8%), and had a higher total leuko-
cyte count on admission (9.4 ± 7.4 vs.
6.2  ± 3.2 x 109/L). No differences
were found in the lactate dehydroge-
nase, activated partial thromboplastin
time, creatinine phosphokinase, and
alanine-aminotransferase levels
between the two groups. 
Fifteen of the 22 seronegative
patients responded to antibiotics (8);
five died of comorbid illnesses (one of
carcinoma of lung, one of metastatic
carcinoma of prostate, two of chronic
pulmonary diseases, and one of con-
gestive heart failure), and two died of
bacterial pneumonia. In four patients,
bacterial pathogens were identified
(one methicillin-resistant Staphyl-
ococcus aureus, two Stenotropho-
monas maltophilia, and one Pseudo-
monas aeruginosa). Also, 15 (68.2%)
of the patients had coexisting medical
conditions: three had congestive heart
failure, four had chronic pulmonary
diseases, two had chronic renal fail-
ures, two had advanced malignancies,
two had diabetes mellitus, and two
had Parkinson’s disease.
Our findings showed that 5.9% of
cases defined as probable SARS on
the basis of clinical-epidemiologic
criteria had no serologic evidence of
coronavirus infection. This set of cri-
teria was associated with a PPV as
high as 0.94 in a local outbreak. The
PPV of the CDC epidemiologic crite-
rion of close contact was higher
(0.98). The PPV of possible contact
was 0.67, but when applied with lym-
phopenia, the PPV became higher.
Our analysis illustrated that a history
of close contact with patients with
SARS-CoV infection is of major
importance when diagnosing such
infection. This finding supports the
hypothesis that SARS-CoV is trans-
mitted through respiratory droplets
and physical contact with a patient’s
body fluids. Although not specific,
lymphopenia and its subsequent
progress was highly prevalent among
SARS patients (8–10). Clinicians are
now advised by the World Health
Organization that hematologic devia-
tions (e.g., lymphopenia) should be
considered in SARS evaluations (1). 
Our study was limited by sample
size and its retrospective status.
Nonetheless, we demonstrated the
accuracy of diagnostic criteria in an
outbreak and the importance of epi-
demiologic criteria. Further studies
are needed to evaluate the diagnostic
accuracy of these criteria in a nonout-
break situation when the case preva-
lence is low.
Louis Y. Chan,* Nelson Lee,† 
Paul K.S. Chan,† Alan Wu,†
Timothy H. Rainer,† Philip K.T. Li,*
Hong Fung,* and Joseph JY Sung†
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Table. SARS contact history and demographic and initial laboratory parameters in 
seropositive and seronegative patients 
  Seropositive 
patients,  
n = 353 (%) 
Seronegative 
patients,  
n = 22 (%) 
p value or OR 
(95% CI)
a 
Demographic data       
    Age   40.9 ± 17.2  51.2 ± 24.3  0.008 
    Healthcare workers (HCW)  193 (54.7)  2 (9.1) 
    Non-HCW  160 (45.3)  20 (90.9) 
12.1 (2.8 to 52.4) 
Laboratory parameters on 
admission 
 
    Total leukocyte count (x 10
9/L)  6.2 ± 3.2  9.4 ± 7.4  < 0.001 
    Lymphocyte count (x 10
9/L)  1.0 ± 0.4  1.2 ± 0.8  0.027 
Level of contact   
   Definite close contact  322 (91.2)  7 (31.8) 
   Possible contact  31 (8.8)  15 (68.2) 
22.3 (8.4 to 58.7) 
Possible contact plus 
lymphopenia 
 
    Lymphocyte < 0.8 x 10
9/L  13 (76.5)  4 (23.5)   
    Lymphocyte < 1.0 x 10
9/L  21 (72.4)  8 (27.6)   
Venue of contact   
    Hospital  290 (82.2)  8 (36.4) 
    Community  63 (17.8)  14 (63.6) 
8.1 (3.2 to 20.0) 
aOR, odds ratio; CI, confidence interval.  LETTERS
*Prince of Wales Hospital, Hong Kong,
Special Administrative Region (SAR); and
†The Chinese University of Hong Kong,
Hong Kong, SAR
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To the Editor: Malaria continues
to cause disease and death in millions
of persons living in areas of the world
where it is endemic, despite 4 decades
of research on vaccines, new drugs,
and alternative methods of control.
Still, by far the most effective method
for reducing and controlling the
impact of this disease is indoor resid-
ual spraying (IRS) of insecticides.
The most cost-effective and safe
insecticide has been, and in many
instances still is, dichlorodiphenyl-
trichloroethane (DDT). This interven-
tion is continually under scrutiny, and
we address these issues in this letter.
Chen and Rogan (1) claim that
DDT causes reduced duration of lac-
tation and increased incidence of
preterm births, and they posit that
DDT used for malaria control would
do as much harm as good. The valid-
ity of their arguments requires sub-
stantial evidence of a causal relation-
ship between DDT and adverse con-
sequences of DDT IRS for malaria
control. 
Chen and Rogan dismiss a field
study on births and duration of lacta-
tion in South African mothers, some
of whom occupied houses sprayed
with DDT for malaria control (2).
However, if claims of large numbers
of adverse health effects of DDT IRS
are correct, then the study should have
detected large differences between
DDT-exposed and unexposed popula-
tions. According to Chen and Rogan,
the median duration of breastfeeding
could be as low as 3–4 months when
mothers are exposed to high levels of
DDT. Thus, a cross-section of breast-
feeding infants in the DDT-exposed
population should, on average, have
been considerably younger than in the
unexposed population. In fact, the
average age of breastfeeding infants
was slightly greater in the DDT-
exposed population (8.3 months ver-
sus 7.7 months). For both populations,
only an insignificant fraction of moth-
ers could not donate milk.
Furthermore, twice the level of
dichlordiphenylethylene (DDE, meta-
bolic breakdown product of DDT)
that is claimed to cause reduced dura-
tion of lactation in humans has no
adverse affect on lactation in rats (3).
The authors of the South African
study (2) report no difference in rates
of stillbirths between the sprayed and
unsprayed areas.
The National Institute of Environ-
mental Health Sciences study (4)
reported a causal association between
DDT and preterm and small-for-ges-
tational-age births but this has not
been replicated for African births.
The study was not based on a random
population of births, and no explana-
tion is offered for including diverse
categories of births in the study pop-
ulation.
An earlier study in Sri Lanka pre-
sented data on deaths attributed to
malaria and to premature births years
before DDT was used and years when
DDT IRS was used in 21 districts (5).
Districts varied greatly in levels of
malaria endemicity. After DDT was
introduced in 1946, levels of IRS in
21 districts were commensurate with
levels of endemic malaria. After 1946,
malaria deaths declined greatly and
the reduction was greatest where
DDT usage was highest. During the
same period, deaths attributable to
premature births increased slightly.
Inves-tigators attributed this to
“improvements in reporting and diag-
nosis rather than any declines in the
health of expectant mothers, which on
all other criteria showed improve-
ment.” (5). Spearman’s correlation
analysis for 21 districts shows that the
increase in premature birth deaths was
slightly greater in areas with less
malaria and DDT use. Thus, the evi-
dence does not support the idea that
the reported increase in premature
births was a side effect of DDT use. In
any case, the increase in deaths attrib-
utable to premature births was orders
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